Historical clx News Stories
Clorox Faces Downgrade, Debt Strain After GOJO Buy
Clorox (CLX) saw a near‑term analyst downgrade tied to margin compression and softer consumer demand while filings reveal a $2.25B GOJO acquisition financed with a $1B revolver and $1.25B term loan—raising leverage and integration scrutiny.
Clorox Downgraded: Sell -CLX Faces Margin Pressure
A major Wall Street firm downgraded Clorox (CLX) to Sell on March 2, 2026, citing margin erosion from elevated input costs and shifting consumer behavior toward private-labels. Broader CPG pressures — notably packaging and tariff-driven cost increases — compound near-term headwinds for the company.
Clorox Q2 Results, ERP Finish and GOJO Takeover
Clorox reported modest revenue decline and an EPS drop in Q2 FY2026 while completing a major ERP rollout and moving to acquire GOJO. The mix of operational milestones, a regulatory fine, and reaffirmed full-year guidance drove muted stock reactions and leaves margin recovery and integration execution as key near-term catalysts.
Clorox Q2 Results: Margin Pressure Stable Dividend
Clorox’s Q2 FY2026 report showed modest sales decline, margin compression and lower EPS, but management reaffirmed full-year guidance. Near-term performance hinges on ERP-related inventory shifts and the pending GOJO acquisition while steady dividend and strong YTD stock returns keep investor interest.
Clorox Rally: GOJO Deal, Q2 Miss and Outlook Ahead
Clorox shares climbed after a four‑day rally as Q2 results showed an EPS miss but stable sales, a $2.25B GOJO acquisition, ERP normalization and modest fines. Investors watch integration, margin recovery and cash flow.
Clorox Q2 Results, GOJO Deal Drive CLX Rally Redux
Clorox’s Q2 FY2026 showed modest revenue and EPS declines amid ERP-related shipment timing, while the $2.25B GOJO (Purell) acquisition and steady cash flow helped spur a multiday stock rally. Investors are watching ERP normalization, synergy capture, and integration timing as near-term catalysts for CLX.